These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27270208)

  • 1. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Rosebush JC; Shapiro AM; Schwartz MH; Eckard AR; Amogne W; Abebe W
    J Biomech; 2016 Sep; 49(13):2584-2592. PubMed ID: 27270208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
    Gleason RL; Caulk AW; Seifu D; Parker I; Vidakovic B; Getenet H; Assefa G; Amogne W
    PLoS One; 2015; 10(4):e0117125. PubMed ID: 25915208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
    Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
    Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
    Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
    Domingo P; Gutierrez Mdel M; Gallego-Escuredo JM; Torres F; Mateo MG; Villarroya J; Lamarca K; Domingo JC; Vidal F; Villarroya F; Giralt M
    J Acquir Immune Defic Syndr; 2014 Aug; 66(5):457-65. PubMed ID: 24820106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
    McDonald CR; Conroy AL; Gamble JL; Papp E; Hawkes M; Olwoch P; Natureeba P; Kamya M; Silverman M; Cohan D; Koss CA; Dorsey G; Kain KC; Serghides L
    Clin Infect Dis; 2018 Jan; 66(3):428-436. PubMed ID: 29136115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
    Koss CA; Natureeba P; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Clark TD; Achan J; Ruel T; Nzarubara B; Kamya MR; Havlir DV; Cohan D
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):128-35. PubMed ID: 25072616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
    Vieira CS; Bahamondes MV; de Souza RM; Brito MB; Rocha Prandini TR; Amaral E; Bahamondes L; Duarte G; Quintana SM; Scaranari C; Ferriani RA
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):378-85. PubMed ID: 24798768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
    Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
    J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
    Shaffer D; Hughes MD; Sawe F; Bao Y; Moses A; Hogg E; Lockman S; Currier J
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):155-63. PubMed ID: 24562349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy.
    Dejkhamron P; Unachak K; Aurpibul L; Sirisanthana V
    J Pediatr Endocrinol Metab; 2014 May; 27(5-6):403-12. PubMed ID: 24259240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
    Maggi P; Bellacosa C; Leone A; Volpe A; Ricci ED; Ladisa N; Cicalini S; Grilli E; Viglietti R; Chirianni A; Bellazzi LI; Maserati R; Martinelli C; Corsi P; Celesia BM; Sozio F; Angarano G
    Atherosclerosis; 2017 Aug; 263():398-404. PubMed ID: 28522147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
    Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
    Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
    Liu X; Ma Q; Zhao Y; Mu W; Sun X; Cheng Y; Zhang H; Ma Y; Zhang F
    Pharmacotherapy; 2017 Sep; 37(9):1073-1080. PubMed ID: 28718515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
    Squillace N; Trabattoni D; Muscatello A; Sabbatini F; Maloberti A; Giannattasio C; Masetti M; Fenizia C; Soria A; Clerici M; Gori A; Bandera A
    J Antimicrob Chemother; 2018 Aug; 73(8):2162-2170. PubMed ID: 29897513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
    Sierra-Madero J; Villasis-Keever A; Méndez P; Mosqueda-Gómez JL; Torres-Escobar I; Gutiérrez-Escolano F; Juárez-Kasusky I; Magana-Aquino M; Ramos-Santos C; Pérez-Saleme L; Rangel-Frausto S; Antuna-Puente B; Soto-Ramírez LE; Lima V; Belaunzarán-Zamudio F; Crabtree-Ramírez B; Montaner J
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
    Rojas J; Lonca M; Imaz A; Estrada V; Asensi V; Miralles C; Domingo P; Montero M; del Rio L; Fontdevila J; Perez I; Cruceta A; Gatell JM; Arnedo M; Martínez E
    HIV Med; 2016 May; 17(5):340-9. PubMed ID: 27089862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.